Abstract
Background: Acute rejection (AR) is the predominant form of rejection observed in liver transplantation and plays a crucial role in transplant immunology. This study aims to utilize bibliometric analysis to understand the status quo, hotspots, and future trends of research on AR after liver transplantation.
Methods: We searched the Web of Science Core Collection (WoSCC) for studies on AR after liver transplantation published from 1988 to 2022. The Bibliometric Online Analysis Platform, VOSviewer, and CiteSpace were used for analysis of all extracted publications.
Results: This study included 2,398 articles published in 456 journals by 12,568 authors from 1,965 institutions in 55 countries/regions. The United States and its affiliated institution, the University of Pittsburgh, were the most productive contributors. Transplantation (n = 12,435) was the most frequently cited journal. Neuhaus P (n = 38) was the highest output author, and Demetris AJ (n = 670) was the most co-cited author. The research hotspots of AR after liver transplantation include pathogenesis, immunosuppressive therapy, and prognosis. Emerging research directions include regulatory T cells, immunosuppression minimization, intra-patient variability (IPV) of tacrolimus, and novel non-invasive diagnostic markers.
Conclusion: Our study utilized bibliometric methods to analyze the study of AR after liver transplantation over the past 35 years. With the prolonged survival of liver transplant recipients, the most active areas currently focus on individualized treatment and improving patient prognosis. Minimizing adverse reactions to immunosuppressive therapy while simultaneously avoiding an increase in the risk of AR remains a future research focus.
1 Introduction
In 1963, Starzl TE performed the worldās first case of liver allograft on a child with congenital biliary atresia, but unfortunately, the child died on the operating table due to massive bleeding (Starzl et al., 1964). After that, Starzl TE performed several human liver transplant operations, but the survival time of the recipients did not exceed 1 month. Afterwards, the possible causes of the failure were analyzed, and it was found that AR was one of the most important factors affecting the early prognosis after liver transplantation (Starzl et al., 1968). With the development of organ preservation methods, surgical techniques, and immunosuppressive therapy, especially the application of the new immunosuppressant tacrolimus FK506, the incidence of AR after liver transplantation has been greatly reduced, and the postoperative survival rate and survival time have been significantly improved (Todo et al., 1994; Song et al., 2014). At present, liver allograft has become the only curative treatment for patients with end-stage liver disease. Research on AR has always been a hotspot and frontier in this field, and many scholars have achieved fruitful results. However, due to the systemic and complex nature of AR after liver transplantation, which involves multiple disciplines and fields, a single perspective from clinical analysis or basic research may not provide a comprehensive understanding. Conducting bibliometric analysis might be a promising approach.
The concept of bibliometrics was first introduced by Alan Pritchard in 1969 (). Bibliometric analysis is a method that utilizes mathematical, statistical techniques, and visualization tools to analyze parameters such as publication count, countries/regions, journals, authors, and keywords. By conducting comprehensive analyses of publications in a specific field, bibliometric analysis provides a detailed overview of the knowledge landscape and enables researchers to understand the latest research trends. Compared to other methods such as reviews or meta-analyses, bibliometric analysis offers unique advantages. Common bibliometric software packages include CiteSpace, VOSviewer, UCINET, SciMAT, Pajek, and Bicomb, among which CiteSpace and VOSviewer are the most widely used together (; Vargas et al., 2022).
To the best of our knowledge, no bibliometric study on AR after liver transplantation has been reported globally to date. Researchers have previously analyzed clinical liver transplantation in the past 40Ā years (), and immunology-related AR, as an important branch, has not been fully analyzed by the author. Therefore, this article comprehensively analyses the research hotspots and emerging trends of AR after liver transplantation during 1988ā2022 by combining bibliometric methods, providing a systematic review, and forming corresponding visual maps. This study provides scholars in this field with the current overall framework of AR after liver transplantation, showing the knowledge base, evolutionary path, research frontiers and future research trends.
2 Materials and methods
2.1 Data selection
As one of the most influential databases for literature, Web of Science (WoS) is widely regarded as the optimal tool for conducting bibliometric analysis, and many researchers have utilized the WoS database to publish bibliometric studies (Thelwall, 2008; ). Thus, on 8 January 2023, we conducted a search and extracted literature data from the WoSCC database. Using Boolean logical operators, we employed the following search strategy: TS= (āliver graft*ā OR āliver transplant*ā OR āhepatic transplant*ā) AND TS= (āacute rejectionā OR āacute graft rejectionā OR āacute transplant rejectionā). Only literature from the Science Citation Index Expanded (SCI-E) was selected. The retrieval time frame spanned from 1 January 1988, to 31 December 2022, with article types limited to āArticleā or āReviewā and language limited to English. Ultimately, we analyzed 2,398 articles that met our criteria. A detailed screening process is presented in Figure 1.
FIGURE 1
2.2 Data analysis and visualization
We imported the downloaded data from WoS into the Bibliometric Online Analysis Platform (https://bibliometric.com/app), which enabled us to visualize the annual publication trends and collaboration relationships among different countries/regions. VOSviewer is a free bibliometric mapping software that produces various visual maps such as network and density visualization of institutions, journals, authors, and keywords (Van Eck and Waltman, 2010). CiteSpace, a scientific literature visualization software developed by Professor Chaomei Chen, generates a cluster view and timeline view to summarize the knowledge base and research frontiers of the relevant field (). This can provide insight into potential research hotspots and trends. In this study, we utilized CiteSpace [version 6.1.R3 (64-bit)] as a supplement to VOSviewer. The parameters in CiteSpace were set as follows: Link Retaining Factor (LRF = 3), Look Back Years (LBY = 5), e for Top N (e = 1), Time Span (1988ā2022), Years Per Slice (Starzl et al., 1964), Selection Criteria (g-index: k = 25), and Minimum Duration (MD = 1). The integration of these bibliometric software tools can provide a comprehensive analysis and display of literature data, unveiling various characteristics and trends in the studied field.
3 Results
3.1 Annual growth trend of publications
From 1 January 1988, to 31 December 2022, a total of 2,398 publications related to AR after liver transplantation were identified in the WoSCC database. As shown in Figure 2, there were relatively fewer articles on AR after liver transplantation before the 1990s. However, since the 1990s, publications have increased steadily. It reached its peak in 2005 (n = 126) and then experienced a noticeable decline in 2007. However, in the following 5Ā years, the number of publications steadily increased. From 2011 to the present, there has been a fluctuating downwards trend in the number of publications, but the annual publication count has remained above 60.
FIGURE 2
3.2 Productive countries/regions and institutions
These 2,398 articles were published by 1,965 institutions from 55 countries/regions. As shown in Table 1, the United States (n = 609), China (n = 363), and Germany (n = 236) are the three countries with the highest cumulative publication volumes. Figure 3A displays the annual publication trends of the top 10 countries in terms of total publication count. Notably, although the United States has long dominated the research on AR after liver transplantation, China (n = 19) surpassed the United States (n = 13) in terms of annual publications for the first time in 2013 and has consistently remained ahead in recent years. Figure 3B illustrates the collaboration between different countries. Publications from the United States and European countries have relatively earlier publication dates, whereas articles from Asian countries, including China, South Korea, and India, have predominantly been published in the last decade (Figure 3C). Figure 3D provides a geographical visualization of the countries involved in research related to AR after liver transplantation.
TABLE 1
| Rank | Country/Region | Count | Average citations per publication | Rank | Institution | Count | Average citations per publication |
|---|---|---|---|---|---|---|---|
| 1 | United States | 609 | 47 | 1 | Univ Pittsburgh | 66 | 63 |
| 2 | China | 363 | 12 | 2 | Zhejiang Univ | 54 | 17 |
| 3 | Germany | 236 | 37 | 3 | Univ Calif San Francisco | 45 | 99 |
| 4 | Spain | 197 | 32 | 4 | Stanford Univ | 34 | 42 |
| 5 | Japan | 182 | 22 | 5 | Univ Calif Los Angeles | 34 | 71 |
| 6 | France | 162 | 39 | 6 | Hannover Med Sch | 33 | 49 |
| 7 | United Kingdom | 161 | 47 | 7 | Univ Minnesota | 32 | 60 |
| 8 | Italy | 150 | 33 | 8 | Chongqing Med Univ | 31 | 13 |
| 9 | Canada | 108 | 40 | 9 | Shanghai Jiao Tong Univ | 31 | 10 |
| 10 | Netherlands | 87 | 40 | 10 | Univ Toronto | 31 | 33 |
The top 10 countries/regions and institutions associated with AR after liver transplantation.
FIGURE 3
For the institutions, the University of Pittsburgh (n = 66) is the most productive institution, followed by Zhejiang University (n = 54) and the University of California, San Francisco (n = 45) (Table 1). The University of California, San Francisco is the institution with the highest average citations per article among the top ten institutions. Among the top ten institutions, five are from the United States, while three are from China. Figure 4 shows the cooperative relationship between institutions. In contrast to collaboration between countries, there is closer collaboration among domestic institutions.
FIGURE 4
3.3 Productive journals and co-cited journals
A total of 456 journals published literature on AR after liver transplantation and cited references from 4,796 journals. Table 2 displays the top 10 journals in terms of publication count and co-cited journals. Transplantation Proceedings ranked highest with 334 articles published. Among the co-cited journals, Transplantation ranked first by a significant margin and was the only journal with over 10,000 citations. Among all the co-cited journals, a density map was generated for the top 1,000 journals with the highest total link strength, providing a clear visualization of highly cited journals in Figure 5.
TABLE 2
| Rank | Journal | Count | Q | Rank | Co-cited journal | TC | Q |
|---|---|---|---|---|---|---|---|
| 1 | Transplantation Proceedings | 334 | Q4 | 1 | Transplantation | 12,435 | Q1 |
| 2 | Transplantation | 286 | Q1 | 2 | Transplant Proceedings | 6,432 | Q4 |
| 3 | Liver Transplantation | 157 | Q1 | 3 | Liver Transplantation | 4,521 | Q1 |
| 4 | American Journal of Transplantation | 94 | Q1 | 4 | Am J Transplant | 4,107 | Q1 |
| 5 | Clinical Transplantation | 89 | Q2 | 5 | Hepatology | 3,851 | Q1 |
| 6 | Pediatric Transplantation | 78 | Q3 | 6 | Lancet | 1,577 | Q1 |
| 7 | Transplant International | 65 | Q1 | 7 | New Engl J Med | 1,568 | Q1 |
| 8 | Transplant Immunology | 51 | Q4 | 8 | Clin Transplant | 1,496 | Q2 |
| 9 | Hepatology | 43 | Q1 | 9 | J Hepatol | 1,431 | Q1 |
| 10 | Annals of Transplantation | 42 | Q4 | 10 | J Immunol | 1,368 | Q2 |
The top 10 journals and co-cited journals associated with AR after liver transplantation.
TC, total citation; Q Quartile in category.
FIGURE 5
The dual map overlay feature of CiteSpace was used to display the distribution of journal topics at the disciplinary level, revealing the overall scientific contribution (). As shown in Figure 6, there are three distinct citation pathways. The two green citation pathways indicate that literature published in Medicine/Medical/Clinical journals primarily cites literature from Molecular/Biology/Genetics and Health/Nursing/Medicine journals. The orange pathway indicates that literature published in Molecular/Biology/Immunology journals primarily cites literature from Molecular/Biology/Genetics journals.
FIGURE 6
3.4 Productive authors and co-cited authors
The bibliometric analysis results showed that 12,568 authors participated in research related to liver transplant rejection, citing a total of 29,629 authorsā articles. As shown in Table 3, Neuhaus P (n = 38) ranked first in terms of publication count, followed by Muro M (n = 37), Zheng SS (n = 37), Metselaar HJ (n = 35), and Nashan B (n = 33). In terms of co-cited authors, the top 10 authors were cited more than one hundred times, with Demetris AJ (n = 670) being the most cited author, followed by Starzl TE (n = 530), Wiesner RH (n = 308), Berenguer M (n = 274), and Neuhaus P (n = 219). Additionally, we used VOSviewer to draw a network map based on the collaboration between authors (Figure 7A). Different colors represent different clusters, there is a closer collaboration between authors within the same cluster. Neuhaus P, Samuel D, and Metselaar HJ from different clusters also have good collaborative relationships. Furthermore, there were 1,366 authors with co-cited exceeding 10, a density map was created for the top 1,000 authors with the highest total link strength (Figure 7B), where the levels of yellow and font size clearly indicate highly co-cited authors. It is evident that Demetris AJ is the most frequently cited author in this field.
TABLE 3
| Rank | Author | Count | Rank | Co-cited author | TC |
|---|---|---|---|---|---|
| 1 | Neuhaus P | 38 | 1 | Demetris Aj | 670 |
| 2 | Muro M | 37 | 2 | Starzl Te | 530 |
| 3 | Zheng Shusen | 37 | 3 | Wiesner Rh | 308 |
| 4 | Metselaar Hj | 35 | 4 | Berenguer M | 274 |
| 5 | Nashan B | 33 | 5 | Neuhaus P | 219 |
| 6 | Minguela A | 32 | 6 | Kamada N | 202 |
| 7 | Alvarez-Lopez Mr | 25 | 7 | Kahan Bd | 201 |
| 8 | Reding R | 25 | 8 | Jain A | 187 |
| 9 | Samuel D | 25 | 9 | Busuttil Rw | 173 |
| 10 | Saliba F | 24 | 10 | Singh N | 150 |
The top 10 authors and co-cited authors related to AR after liver transplantation.
FIGURE 7
3.5 Keyword co-occurrence, clusters, and evolution
A total of 5,779 keywords were extracted by using VOSviewer, and we set a threshold of co-occurrence frequency greater than 5 to generate the keyword co-occurrence network after excluding keywords such as āliver transplantationā and āacute rejectionā. Table 4 presents the top 20 high-frequency keywords. As shown in Figure 8A, the keywords can be roughly divided into three clusters: Cluster 1 (32 items, red), Cluster 2 (28 items, green), and Cluster 3 (27 items, blue). In CiteSpace, burst detection reveals keywords that have experienced sudden increases in frequency over time, indicating their significance as active research topics (). We extracted the top 25 keywords with the strongest citation bursts. As exhibited in Figure 8B, keywords such as āantigen,ā āmonoclonal antibody,ā ābiopsy,ā and ācyclosporineā emerged as bursts in the early stage of research, while the current research bursts are mainly focused on keywords such as āregulatory T cell,ā āhepatocellular carcinoma,ā ārenal function,ā āpatients receiving everolimus,ā and āoutcomes."
TABLE 4
| Rank | Keyword | Count | Total link strength | Rank | Keyword | Count | Total link strength |
|---|---|---|---|---|---|---|---|
| 1 | Recipient | 525 | 2022 | 11 | Expression | 153 | 518 |
| 2 | Immunosuppression | 333 | 1,479 | 12 | Hepatitis c virus | 151 | 605 |
| 3 | Fk506 | 298 | 1,300 | 13 | Impact | 146 | 591 |
| 4 | Cyclosporin a | 279 | 1,110 | 14 | Calcineurin inhibitor | 133 | 647 |
| 5 | Risk-factor | 207 | 779 | 15 | Tolerance | 132 | 532 |
| 6 | Survival | 201 | 804 | 16 | Children | 122 | 421 |
| 7 | Disease | 197 | 671 | 17 | Experience | 105 | 372 |
| 8 | Mycophenolate mofetil | 164 | 717 | 18 | T-cell | 103 | 342 |
| 9 | Therapy | 156 | 616 | 19 | Risk | 99 | 367 |
| 10 | Infection | 154 | 607 | 20 | Pharmacokinetics | 98 | 377 |
The top 20 keywords associated with AR after liver transplantation.
FIGURE 8
3.6 Co-cited references and reference burst
Co-cited reference analysis is a method used to analyze the shared citation relationships among publications, revealing core literature, knowledge structure, and development directions in a research field. The top ten reference articles, ranked by citation frequency, are presented in Table 5. The article by an international panel in 1997 (), titled āBanff schema for grading liver allograft rejection: An international consensus document,ā has the highest citation count.
TABLE 5
| Rank | Title | TC | Year | Journal |
|---|---|---|---|---|
| 1 | Banff schema for grading liver allograft rejection: an international consensus document | 311 | 1997 | Hepatology |
| 2 | Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome | 116 | 1998 | Hepatology |
| 3 | Chronic renal failure after transplantation of a nonrenal organ | 107 | 2003 | New Engl J Med |
| 4 | Group USMFLS. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation | 102 | 1994 | New Engl J Med |
| 5 | Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection | 91 | 1994 | Lancet |
| 6 | Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel | 63 | 2000 | Hepatology |
| 7 | Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage | 58 | 1979 | Transplantation |
| 8 | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment | 52 | 2001 | Transplantation |
| 9 | Liver allograft rejection. An analysis of the use of biopsy in determining outcome of rejection | 52 | 1987 | Am J Surg Pathol |
| 10 | A surgical experience with five hundred thirty liver transplants in the rat | 52 | 1983 | Surgery |
The top 10 co-cited references associated with AR after liver transplantation.
Analysis of the references within the 5Ā years prior to the publication of the 2,398 articles was conducted to generate clusters that represent research frontiers in different periods. Figure 9A displays a co-cited timeline view clustered using the log-likelihood ratio algorithm. Each node represents a co-cited reference, and the links between nodes indicate that the corresponding references are co-cited within the retrieved set of 2,398 articles. A total of 19 clusters were generated, with the numerical values of the cluster labels negatively correlated with the number of co-cited references in each cluster.
FIGURE 9
Like keywords, co-cited references can also be analyzed for citation bursts. In this bibliometric analysis, 210 references were found to have citation bursts, and Figure 9B shows the top 25 burst references. It is evident that citation bursts typically occur within 2ā3 years after the publication of the referenced papers. From 1995 to 2005, there were multiple papers that experienced citation bursts, and as of 2022, three articles are still in a state of citation bursts.
4 Discussion
4.1 General information
Using the authoritative literature database, WoSCC, we ultimately extracted 2,398 English papers published in the past 35 years (1988ā2022). These papers were authored by 12,568 researchers from 1,965 institutions in 55 countries/regions, published in 456 journals, and cited 48,143 articles published on 4,796 journals by 29,629 authors.
Although the first human liver transplantation was performed as early as 1963, due to the lack of effective immunosuppressive drugs to control AR after surgery, liver transplantation has been controversial (). It was not until 1979 that the British scholar Calne RY first applied the immunosuppressive drug cyclosporine to liver transplantation (Williams et al., 1985), that scholars gradually recognized the effectiveness of liver transplantation and promoted the research on AR after liver transplantation. Therefore, as shown in Figure 1, the 1980s was the starting stage of research on AR after liver transplantation. However, with the gradual clinical application of a new type of immunosuppressive drug (such as FK506 and OKT3) in the late 1980s (; ), the incidence of postoperative AR greatly reduced, and postoperative survival rate and survival time significantly increased. From the 1990s onwards, research on AR after liver transplantation entered a stage of vigorous development and reached its peak in 2005. However, in the following 2Ā years, the number of papers published showed a significant decrease, which may be related to new policies for organ transplantation formulated by various countries during this period (; ). Since 2011, the number of papers related to AR after liver transplantation has shown a fluctuating downwards trend, but has remained above 60 papers per year, indicating that this field has reached a mature stage.
Both at the national and institutional levels, the United States and its affiliated institutions are the most productive in the field of AR after liver transplantation, and their high average citation count demonstrates their absolute authority in the field (Table 1). The progress made by Asian countries in this field is praiseworthy. However, taking China and its affiliated institutions as an example, although the annual publication volume has increased significantly, the average citation count of articles is relatively low. Although this can be partially explained by the relatively recent publication date of the articles, it is more likely due to concerns about the quality of the papers. This phenomenon is not only limited to this field but is also quite common in other fields. Therefore, for Asian countries such as China to enhance their influence in this field, it is necessary to align with international standards, strengthen cooperation between countries and institutions, and publish more high-quality papers in high-impact journals.
Through subject classification searches in WoS, we found that the articles published in the top ten prolific journals primarily focus on the fields of transplantation and immunology. Analyzing prolific journals allows us to understand the core journals in this field and provides suitable journal choices for researchers to publish their papers. Among the top ten highly cited journals, seven belong to the Q1 zone (Table 2), indicating that high-quality articles published in these journals have significantly contributed to the advancement of the field.
Of the top ten productive authors, nine are from Europe. This finding suggests that European researchers play an important role in the study of AR after liver transplantation. Neuhaus P, as the author with the highest publication volume, mainly conducts clinical research on post-transplant immunosuppressive drugs, particularly calcineurin inhibitors (CNIs), mycophenolate mofetil (MMF), and monoclonal antibodies (; ; ). Zheng SS has led multiple studies mainly targeting the prediction of AR after liver transplantation and its influence on prognosis (Wu et al., 2011; ; Wei et al., 2018). Muro Mās research mainly focuses on the pathogenesis and risk factors for AR after liver transplantation (; ; ). Considering co-cited authors, Starzl TE has promoted the clinical application of liver transplantation (Starzl et al., 1964; Starzl et al., 1968). Demetris AJ, Wiesner RH et al. jointly developed histological diagnostic criteria for AR after liver transplantation (). The research achievements of these scholars have laid a foundation for the development of AR-related studies after liver transplantation and made significant contributions to the field.
4.2 Hotspots and frontiers
Through clustering analysis and burst detection of keywords and references, we can quickly grasp the hotspots and evolutionary paths in the field of AR after liver transplantation over the past 35 years and explore emerging research directions. The research focus on AR after liver transplantation has shifted from early understanding of its pathogenesis to the development and application of immunosuppressive agents. Currently, the mainly focus is on the diversity of individual immune conditions, the development of novel immunosuppressive agents, and the regulation of immune tolerance. In addition, developing personalized immunotherapy plans to reduce complications caused by immunosuppression and improve long-term outcomes for patients may be one of the important directions for future research in the field of organ transplantation.
4.2.1 Pathogenesis and diagnosis of AR after liver transplantation
In the 1970s, with advancements in surgical techniques and organ preservation, the success rate of liver transplantation significantly improved. However, due to the high incidence of AR after surgery, the overall one-year survival rate remained below 30% (Zarrinpar and Busuttil, 2013). After in-depth research, scientists discovered that the recognition and attack of allogeneic antigens by the immune system are the core of AR (). CD4+ T cells and CD8+ T cells play a crucial role in AR, participating in immune responses through the production of cytokines and direct cytotoxic pathways (; ; ). Regulatory T cells have become a recent research focus as they inhibit the activation and function of other immune cells, thereby suppressing immune responses and playing a significant protective role in immune balance regulation (; Tanimine et al., 2020). Furthermore, the role of neutrophils in post-liver transplant complications is increasingly gaining attention (). Research indicates that neutrophil extracellular traps (NETs) released by neutrophils can induce inflammatory reactions, exacerbating the severity of AR after liver transplantation by promoting Kupffer cell M1 polarization and HMGB1 intracellular translocation (). Therefore, NETs are considered a potential novel therapeutic target for AR after liver transplantation.
Under the assault of the immune system, liver biopsy exhibits characteristic changes such as damage to bile ducts, endothelial cells, and hepatocytes, as well as the infiltration of inflammatory cells (Snover et al., 1987; Schlitt et al., 1991). However, liver biopsy is invasive, expensive, and can lead to complications. Researchers are actively seeking non-invasive biomarkers. Through techniques such as single-cell sequencing and proteomic profiling, researchers have discovered biomarkers such as DSA, donor-derived cell-free DNA, CXCL10, and microRNA that can be used to predict the occurrence and severity of AR (; Shaked et al., 2017; ; ). These new findings deepen our understanding of AR after liver transplantation and provide an earlier and safer molecular diagnostic approach ().
4.2.2 Immunosuppressive therapy in liver transplantation
Due to limited understanding of AR, early prevention of AR relied on empirical use of adrenal corticosteroids (such as prednisone) and nitrogen mustard drugs. However, the effectiveness of these medications in preventing rejection was suboptimal, and the occurrence of adverse reactions was a significant concern. With a deeper understanding of transplantation immunology, researchers began developing more specific and effective immunosuppressive drugs. In the 1980s, immunosuppressive agents such as Cyclosporine A and FK506 were introduced, which significantly improve the prognosis of liver transplant recipients by inhibiting the activity of T lymphocytes and reducing the occurrence of rejection. Subsequently, researchers continuously explored more personalized and targeted immunosuppression strategies. Novel immunosuppressive drugs, including anti-proliferative/metabolic agents (such as MMF) and mTOR inhibitors (such as sirolimus and everolimus), have been introduced into the immunosuppressive regimens (; Saliba et al., 2017). This has greatly enhanced the long-term survival rate of liver transplant recipients.
4.2.3 Management of long-term complications after liver transplantation
With the extended survival of liver transplant recipients, there is a growing emphasis on improving quality of life. Researchers and clinicians are increasingly concerned about the management of long-term complications, particularly the adverse effects associated with the prolonged use of immunosuppressive agents. These effects mainly include opportunistic infections, renal dysfunction, neurological damage, and recurrence of malignancies, which are major factors affecting long-term survival of patients (; ; ). To address these issues, researchers have focused on immunosuppression minimization strategies (). They have found individual variations in the response to immunosuppressive agents among recipients, and even observed transplant tolerance in some cases (; ; ). Researchers are also continuously developing new immunosuppressive drugs to replace corticosteroids and CNIs, aiming to reduce their nephrotoxicity and neurotoxicity. For liver transplant patients with malignancies, clinicians have shifted their approach, using immune checkpoint inhibitors (such as Programmed Cell Death 1 Inhibitor) to prevent tumor recurrence (). However, it is important to be cautious about the potential risk of AR when implementing these strategies.
5 Strengths and limitations
Compared to traditional reviews, bibliometric analysis provides a more comprehensive overview of the literature in a research field by covering many literature resources. The use of objective metrics and analysis methods enhances the reliability of the conclusions. However, our study also has some limitations. First, we only extracted literature from the SCI-E of the WoSCC database, while other important databases such as PubMed and Scopus were not included. Additionally, we imposed restrictions on the time, language, and types of literature, which may have resulted in the omission of important studies. Second, bibliometric analysis usually focuses on the analysis of quantity and trends, but it has limitations in providing in-depth understanding and interpretation of the research content. It cannot replace systematic reviews and analyses of specific research questions. Nevertheless, bibliometric visualization analysis undoubtedly provides scholars with a more convenient way to understand the research topics, hotspots, and their evolution of AR after liver transplantation. It also provides guidance for exploring valuable research directions.
6 Conclusion and future perspective
Acute rejection, as the most common type of transplant rejection, is a crucial aspect of research in transplantation immunology. In this comprehensive bibliometric analysis, we examined the literature related to AR after liver transplantation published from 1988 to 2022. Our analysis revealed the main countries, institutions, journals, and authors in this research field, as well as the knowledge base and evolving hotspots. The results showed that this field has matured after 35 years of development. The latest research topics and hotspots are centered around the management of adverse reactions to immunosuppressive agents, immunosuppression minimization, IPV of tacrolimus, and novel non-invasive diagnostic biomarkers. We anticipate that in the future, with the prolonged survival of transplant recipients, individualized treatment plans and improving patient prognosis will remain the key focus of research. Attaining a subtle balance between optimal immunosuppression and minimal side effects is an urgent issue.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Author contributions
ZX: Methodology, Software, Visualization, Writingāoriginal draft. ZY: Data curation, Investigation, Software, Validation, Writingāoriginal draft. QW: Conceptualization, Methodology, Supervision, Writingāreview and editing. TL: Conceptualization, Methodology, Validation, Writingāreview and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by Hunan Provincial Innovation Foundation for Postgraduate (CX20230315).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
AR, acute rejection; CNIs, calcineurin inhibitors; DSA, donor-specific antibody; IPV, intra-patient variability; MMF, mycophenolate mofetil; WoS, Web of Science; WoSCC, Web of Science Core Collection.
References
1
AdamsD. H.MainolfiE.EliasE.NeubergerJ. M.RothleinR. (1993). Detection of circulating intercellular adhesion molecule-1 after liver transplantation--evidence of local release within the liver during graft rejection. Transplantation55 (1), 83ā87. 10.1097/00007890-199301000-00016
2
AdamsD. H.Sanchez-FueyoA.SamuelD. (2015). From immunosuppression to tolerance. J. Hepatol.62 (1 Suppl. l), S170āS185. 10.1016/j.jhep.2015.02.042
3
Bonaccorsi-RianiE.PennycuickA.LondonoM. C.LozanoJ. J.BenitezC.SawitzkiB.et al (2016). Molecular characterization of acute cellular rejection occurring during intentional immunosuppression withdrawal in liver transplantation. Am. J. Transpl.16 (2), 484ā496. 10.1111/ajt.13488
4
ChenC. (2006). CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J. Am. Soc. Inf. Sci. Technol.57 (3), 359ā377. 10.1002/asi.20317
5
ChenC. (2016). CiteSpace: a practical guide for mapping scientific literature. Hauppauge, NY, USA: Nova Science Publishers.
6
DingX.YangZ. (2020). Knowledge mapping of platform research: a visual analysis using VOSviewer and CiteSpace. Electron. Commer. Res.22, 787ā809. 10.1007/s10660-020-09410-7
7
DonaldsonP.UnderhillJ.DohertyD.HayllarK.CalneR.TanK. C.et al (1993). Influence of human leukocyte antigen matching on liver allograft survival and rejection: "the dualistic effect. Hepatology17 (6), 1008ā1015. 10.1002/hep.1840170611
8
ElS. A.MohamedI. B.AloorF. Z.AbdelwahabA.HassanM. M.JalalP. K. (2023). Current status of biomarkers and molecular diagnostic tools for rejection in liver transplantation: light at the end of the tunnel?J. Clin. Exp. Hepatol.13 (1), 139ā148. 10.1016/j.jceh.2022.06.010
9
FungJ. J.TodoS.JainA.McCauleyJ.AlessianiM.ScottiC.et al (1990). Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transpl. Proc.22 (1), 6ā12.
10
Garcia-AlonsoA. M.MinguelaA.MuroM.OntanonJ.TorioA.MarinL.et al (1997). CD28 expression on peripheral blood T lymphocytes after orthotopic liver transplant: upregulation in acute rejection. Hum. Immunol.53 (1), 64ā72. 10.1016/S0198-8859(97)00026-8
11
GeisslerE. K.SchlittH. J. (2009). Immunosuppression for liver transplantation. Gut58 (3), 452ā463. 10.1136/gut.2008.163527
12
HanJ. W.JooD. J.KimJ. H.RhaM. S.KohJ. Y.ParkH. J.et al (2020). Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction. Am. J. Transpl.20 (8), 2058ā2069. 10.1111/ajt.15789
13
Hepatology (1997). Banff schema for grading liver allograft rejection: an international consensus document. Hepatology25 (3), 658ā663. 10.1002/hep.510250328
14
HoffmannM. W.WonigeitK.SteinhoffG.HerzbeckH.FladH. D.PichlmayrR. (1993). Production of cytokines (TNF-alpha, IL-1-beta) and endothelial cell activation in human liver allograft rejection. Transplantation55 (2), 329ā335. 10.1097/00007890-199302000-00019
15
HuangJ. (2007). Ethical and legislative perspectives on liver transplantation in the People's Republic of China. Liver Transpl.13 (2), 193ā196. 10.1002/lt.21081
16
JiangD.JiT.LiuW.BednarschJ.SelznerM.PratschkeJ.et al (2022). Four decades of clinical liver transplantation research: results of a comprehensive bibliometric analysis. Transplantation106 (10), 1897ā1908. 10.1097/TP.0000000000004224
17
JinX.ZhangK.FangT.ZengX.YanX.TangJ.et al (2022). Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: case report and literature review. Front. Oncol.12, 951303. 10.3389/fonc.2022.951303
18
JucaudV.ShakedA.DesMaraisM.SayreP.FengS.LevitskyJ.et al (2019). Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients. Hepatology69 (3), 1273ā1286. 10.1002/hep.30281
19
KimJ. M.KwonC. H.JohJ. W.SinnD. H.LeeS.ChoiG. S.et al (2016). Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: a randomized prospective study. Liver Transpl.22 (2), 209ā216. 10.1002/lt.24336
20
KluppJ.BechsteinW. O.PlatzK. P.KeckH.LemmensH. P.KnoopM.et al (1997). Mycophenolate mofetil added to immunosuppression after liver transplantation--first results. Transpl. Int.10 (3), 223ā228. 10.1007/s001470050046
21
KluppJ.PfitzmannR.LangrehrJ. M.NeuhausP. (2005). Indications of mycophenolate mofetil in liver transplantation. Transplantation80 (1 Suppl. l), S142āS146. 10.1097/01.tp.0000187133.53916.8f
22
KuypersD. R. J. (2020). Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome. Clin. Pharmacol. Ther.107 (2), 347ā358. 10.1002/cpt.1618
23
LevitskyJ.AsraniS. K.SchianoT.MossA.ChavinK.MillerC.et al (2020). Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation. Am. J. Transpl.20 (8), 2173ā2183. 10.1111/ajt.15953
24
LevitskyJ.FengS. (2018). Tolerance in clinical liver transplantation. Hum. Immunol.79 (5), 283ā287. 10.1016/j.humimm.2017.10.007
25
LiuY.PuX.QinX.GongJ.HuangZ.LuoY.et al (2022b). Neutrophil extracellular traps regulate HMGB1 translocation and kupffer cell M1 polarization during acute liver transplantation rejection. Front. Immunol.13, 823511. 10.3389/fimmu.2022.823511
26
LiuY.YanP.BinY.QinX.WuZ. (2022a). Neutrophil extracellular traps and complications of liver transplantation. Front. Immunol.13, 1054753. 10.3389/fimmu.2022.1054753
27
McCaughanG. W.DaviesJ. S.WaughJ. A.BishopG. A.HallB. M.GallagherN. D.et al (1990). A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: the use of monoclonal antibodies and double immunolabeling. Hepatology12 (6), 1305ā1313. 10.1002/hep.1840120610
28
MillisJ. M.McDiarmidS. V.HiattJ. R.BremsJ. J.ColonnaJ. O.2ndKleinA. S.et al (1989). Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation47 (1), 82ā88. 10.1097/00007890-198901000-00019
29
MinguelaA.MarinL.TorioA.MuroM.Garcia-AlonsoA. M.Moya-QuilesM. R.et al (2000). CD28/CTLA-4 and CD80/CD86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant. Hum. Immunol.61 (7), 658ā669. 10.1016/s0198-8859(00)00113-0
30
NeuhausP.BlumhardtG.BechsteinW. O.PlatzK. P.JonasS.MuellerA. R.et al (1995). Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation59 (1), 31ā40. 10.1097/00007890-199501150-00007
31
NeuhausP.ClavienP. A.KitturD.SalizzoniM.RimolaA.AbeywickramaK.et al (2002). Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl.8 (2), 132ā142. 10.1053/jlts.2002.30302
32
NicastroE.GiovannozziS.StroppaP.CasottiV.CallegaroA. P.TebaldiA.et al (2017). Effectiveness of preemptive therapy for cytomegalovirus disease in pediatric liver transplantation. Transplantation101 (4), 804ā810. 10.1097/TP.0000000000001531
33
OntanonJ.MuroM.Garcia-AlonsoA. M.MinguelaA.TorioA.BermejoJ.et al (1998). Effect of partial HLA class I match on acute rejection in viral pre-infected human liver allograft recipients. Transplantation65 (8), 1047ā1053. 10.1097/00007890-199804270-00007
34
PanX.YanE.CuiM.HuaW. (2018). Examining the usage, citation, and diffusion patterns of bibliometric mapping software: a comparative study of three tools. J. Inf.12 (2), 481ā493. 10.1016/j.joi.2018.03.005
35
PritchardA. (1969). Statistical bibliography or bibliometrics. J. documentation25, 348.
36
QiaoZ. Y.ZhangZ. J.LvZ. C.TongH.XiZ. F.WuH. X.et al (2021). Neoadjuvant programmed cell Death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review. Front. Immunol.12, 653437. 10.3389/fimmu.2021.653437
37
RenZ.JiangJ.LuH.ChenX.HeY.ZhangH.et al (2014). Intestinal microbial variation may predict early acute rejection after liver transplantation in rats. Transplantation98 (8), 844ā852. 10.1097/TP.0000000000000334
38
RoscamA. H. D. (2002). A council of europe protocol on transplantation of organs and tissues of human origin. Eur. J. Health Law9 (1), 63ā76. 10.1163/15718090220523735
39
SalibaF.DuvouxC.DharancyS.DumortierJ.CalmusY.GugenheimJ.et al (2019). Early switch from tacrolimus to everolimus after liver transplantation: outcomes at 2 years. Liver Transpl.25 (12), 1822ā1832. 10.1002/lt.25664
40
SalibaF.DuvouxC.GugenheimJ.KamarN.DharancyS.SalameE.et al (2017). Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial. Am. J. Transpl.17 (7), 1843ā1852. 10.1111/ajt.14212
41
SchlittH. J.NashanB.RingeB.BunzendahlH.WittekindC.WonigeitK.et al (1991). Differentiation of liver graft dysfunction by transplant aspiration cytology. Transplantation51 (4), 786ā793. 10.1097/00007890-199104000-00010
42
ShakedA.ChangB. L.BarnesM. R.SayreP.LiY. R.AsareS.et al (2017). An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection. Hepatology65 (1), 269ā280. 10.1002/hep.28786
43
SnoverD. C.FreeseD. K.SharpH. L.BloomerJ. R.NajarianJ. S.AscherN. L. (1987). Liver allograft rejection. An analysis of the use of biopsy in determining outcome of rejection. Am. J. Surg. Pathol.11 (1), 1ā10. 10.1097/00000478-198701000-00001
44
SongA. T.Avelino-SilvaV. I.PecoraR. A.PuglieseV.D'AlbuquerqueL. A.AbdalaE. (2014). Liver transplantation: fifty years of experience. World J. Gastroenterol.20 (18), 5363ā5374. 10.3748/wjg.v20.i18.5363
45
StarzlT. E.GrothC. G.BrettschneiderL.PennI.FulginitiV. A.MoonJ. B.et al (1968). Orthotopic homotransplantation of the human liver. Ann. Surg.168 (3), 392ā415. 10.1097/00000658-196809000-00009
46
StarzlT. E.MarchioroT. L.HuntleyR. T.RifkindD.RowlandsD. T.Jr.DickinsonT. C.et al (1964). Experimental and clinical homotransplantation of the liver. Ann. N. Y. Acad. Sci.120, 739ā765. 10.1111/j.1749-6632.1964.tb34766.x
47
TanimineN.OhiraM.TaharaH.IdeK.TanakaY.OnoeT.et al (2020). Strategies for deliberate induction of immune tolerance in liver transplantation: from preclinical models to clinical application. Front. Immunol.11, 1615. 10.3389/fimmu.2020.01615
48
ThelwallM. (2008). Bibliometrics to webometrics. J. Inf. Sci.34 (4), 605ā621. 10.1177/0165551507087238
49
TodoS.FungJ. J.StarzlT. E.TzakisA.DoyleH.Abu-ElmagdK.et al (1994). Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann. Surg.220 (3), 297ā308. 10.1097/00000658-199409000-00006
50
Van EckN.WaltmanL. (2010). Software survey: VOSviewer, a computer program for bibliometric mapping. scientometrics84 (2), 523ā538. 10.1007/s11192-009-0146-3
51
VargasA. C.Espinoza-MinaM.AlvarezD. L.EspinosaJ. N. (2022). Bibliometric software: the most commonly used in research.
52
WeiQ.WangK.HeZ.KeQ.XuX.ZhengS. (2018). Acute liver allograft rejection after living donor liver transplantation: risk factors and patient survival. Am. J. Med. Sci.356 (1), 23ā29. 10.1016/j.amjms.2018.03.018
53
WilliamsR.CalneR. Y.RollesK.PolsonR. J. (1985). Current results with orthotopic liver grafting in Cambridge/King's College Hospital series. Br. Med. J. Clin. Res. Ed.290 (6461), 49ā52. 10.1136/bmj.290.6461.49
54
WuJ.YeS.XuX.XieH.ZhouL.ZhengS. (2011). Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis. PLoS One6 (1), e16521. 10.1371/journal.pone.0016521
55
ZarrinparA.BusuttilR. W. (2013). Liver transplantation: past, present and future. Nat. Rev. Gastroenterol. Hepatol.10 (7), 434ā440. 10.1038/nrgastro.2013.88
Summary
Keywords
bibliometric analysis, acute rejection, liver transplantation, Citespace, VOSviewer, immunosuppression
Citation
Xiong Z, Yang Z, Wang Q and Li T (2024) Global research hotspots and trends of acute rejection after liver transplantation from 1988 to 2022: a bibliometric analysis. Front. Pharmacol. 15:1357468. doi: 10.3389/fphar.2024.1357468
Received
18 December 2023
Accepted
05 April 2024
Published
17 April 2024
Volume
15 - 2024
Edited by
Paolo De Simone, University of Pisa, Italy
Reviewed by
Salvador F. AliƱo, University of Valencia, Spain
Yanyao Liu, The First Affiliated Hospital of Chongqing Medical University, China
Updates
Copyright
Ā© 2024 Xiong, Yang, Wang and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ting Li, liting001@csu.edu.cn; Qiuguo Wang, 218202105@csu.edu.cn
ā These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.